A novel drug candidate for Alzheimer's disease treatment: Gx-50 derived from zanthoxylum bungeanum

Journal of Alzheimer's Disease

Volumn 34, Issue 1, 2013, Pages 203-213

  Tang, Maoping ^a   Zhou, Ying ^a   Xu, Wangjie ^a   Li, Shengtian ^a   Wang, Lianyun ^a   Wei, Dongqing ^a   Qiao, Zhongdong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Alzheimer's disease; depolymerized amyloid plaque; memory improvement; neuroprotective effect

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CALCIUM; GX 50; NOOTROPIC AGENT; PROTEIN BAX; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATOMIC FORCE MICROSCOPY; BLOOD BRAIN BARRIER; BRAIN CORTEX; CALCIUM CELL LEVEL; COGNITION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MAZE TEST; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WESTERN BLOTTING; ZANTHOXYLUM; ZANTHOXYLUM BUNGEANUM;

EID: 84874333716     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-121831     Document Type: Article

References (30)

1. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W (2004) Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 161, 532-538. (Pubitemid 38326109)
2. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid- in Alzheimer's disease. Nat Rev Neurosci 83, 131-139.
3. Fratiglion L, Wang H-X (2000) Smoking and Parkinson's and Alzheimer's disease: Review of the epidemiological studies. Behav Brain Res 113, 117-120. (Pubitemid 30645549)
4. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
5. Gu R-X, Gu H, Xie Z-Y, Wang J-F, Arias HR, Wei D-Q, Chou K-C (2009) Possible drug candidates for Alzheimer's disease deduced from studying their binding interactions with -7 nicotinic acetylcholine receptor. Med Chem 5, 250-262.
6. Tsai Y-M, Chien C-F, Lin L-C, Tsai T-H (2011) Curcumin and its nano-formulation: The kinetics of tissue distribution and blood-brain barrier penetration. Int J Pharmaceutics 416, 331-338.
7. Lord A, Englund H, Söderberg L, Tucker S, Clausen F, Hillered L, Gordon M, Nilsson LNG (2009) Amyloid-protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J 276, 995-1006.
8. Lord A, Kalimo H, Eckman C, Zhang X-Q, Lannfelt L, Nilsson LNG (2006) The Arctic Alzheimer mutation facilitates early intraneuronal A aggregation and senile plaque formation in transgenic mice. Neurobiol Aging 27, 67-77. (Pubitemid 41627951)
9. Bezprozvanny I (2009) Calcium signaling and neurodegenerative diseases. Trends Mol Med 15, 89-100.
10. Nie B-M, Jiang X-Y, Cai J-X, Fu S-L, Yang L-M, Lin L, Hang Q, Lu Y (2008) Panaxydol and panaxynol protect cultured cortical neurons against A25 35-induced toxicity. Neuropharmacology 54, 845-853.
11. Zeng H, Chen Q, Zhao B (2004) Genistein ameliorates β-amyloid peptide (25-35)-induced hippocampal neuronal apoptosis. Free Radic Biol Med 36, 180-188. (Pubitemid 38117236)
12. Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, BorcheltDR (2005) Persistent amyloidosis following suppression of A production in a transgenic model of Alzheimer disease. PLoS Med 2, 1318-1333. (Pubitemid 43020991)
13. Verret L, Jankowsky JL, Xu GM, Borchelt DR, Rampon C (2007) Alzheimer's-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis. J Neurosci 27, 6771-6780. (Pubitemid 46983445)
14. Lithner CU, Hedberg MM, Nordberg A (2011) Transgenic mice as a model for Alzheimer's disease. Curr Alzheimer Res 8, 818-831.
15. Codita A, Gumucio A, Lannfelt L, Gellerfors P, Winblad B, Mohammed AH, Nilsson LNG (2010) Impaired behavior of female tg-ArcSwe APP mice in the IntelliCage: A longitudinal study. Behav Brain Res 215, 83-94.
16. Rockenstein E, Ubhi K, Pham E, Michael S, Doppler E, Novak P, Inglis C, Masliah E (2011) Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease. J Neurosci Res 89, 1812-1821.
17. Hashimoto R, Senatorov V, Kanai H, Leeds P, Chuang D-M (2003) Lithium stimulates progenitor proliferation in cultured brain neurons. Neuroscience 117, 55-61. (Pubitemid 36246503)
18. Liu X, Zeng J, ZhaoY, Xiao Z, Fang C, Ruan H (2010) Inhibition of ATP-induced Ca2+ Influx by corticosterone in dorsal root ganglion neurons. Neurochem Res 35, 804-810.
19. Arias HR, Gu R-X, Feuerbach D, Guo B-B, Ye Y, Wei DQ (2011) Novel positive allosteric modulators of the human -7 nicotinic acetylcholine receptor. Biochemistry 50, 5263-5278.
20. Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM (2005) Treatment with an amyloid-antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci 25, 6213-6220. (Pubitemid 40923488)
21. Braak H, Braak E (1997) Frequency of stages of Alzheimerrelated lesions in different age categories. Neurobiol Aging 18, 351-357. (Pubitemid 27435070)
22. Fripp J, Bourgeat P, Acosta O, Raniga P, Modat M, Pike KE, Jones G, O'Keefe G, Masters CL, Ames D, Ellis KA, Maruff P, Currie J, Villemagne VL, Rowe CC, Salvado O, Ourselin S (2008) Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. NeuroImage 43, 430-439.
23. Valle-Delgado JJ, Alfonso-Prieto M, De Groot NS, Ventura S, Samitier J, Rovira C, Fernandez-Busquets X (2010) Modulation of A42 fibrillogenesis by glycosaminoglycan structure. FASEB J 24, 4250-4261.
24. Serem WK, Bett CK, Ngunjiri JN, Garno JC (2011) Studies of the growth, evolution, and self-aggregation of β-amyloid fibrils using tapping-mode atomic force microscopy. Microsc Res Techn 74, 699-708.
25. Yao M, Nguyen T-VV, Pike CJ (2005) β-Amyloidinduced neuronal apoptosis involves c-Jun N-terminal kinase-dependent downregulation of Bcl-w. J Neurosci 25, 1149-1158. (Pubitemid 40268956)
26. Adams JM, Cory S (1998) The Bcl-2 protein family: Arbiters of cell survival. Science 281, 1322-1326. (Pubitemid 28406819)
27. Shacka JJ, Roth KA (2005) Regulation of neuronal cell death and neurodegeneration by members of the Bcl-2 family: Therapeutic implications. CNS Neurol Disord Drug Targets 4, 25-39. (Pubitemid 41408406)
28. Hao L, Zhang Q, Yu T, Yu L, Cheng Y (2011) Modulation of ultra-low-molecular-weight heparin on Ca2+]i in nervous cells. Brain Res Bull 86, 355-359.
29. Bezprozvanny I, Mattson MP (2008) Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci 31, 454-463.
30. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 8, 101-112. (Pubitemid 46432529)